The FDA has issued a safety announcement for the SGLT2 inhibitors used in the management of diabetes (dapagliflozin and empagliflozin are available in South Africa).

They warn of a rare side-effect called Fournier’s gangrene (necrotising fasciitis of the perineum). Read the safety announcement here.